A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

The anti-VEGF antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Theoretically, vascular endothelial growth factor receptors (VEGFRs)-specific cytotoxic T lymphocytes (CTLs) can kill both tumor vessel cells and tumor cells expressing VEGFRs. Here we show an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Tamura, Ryota, Fujioka, Masato, Morimoto, Yukina, Ohara, Kentaro, Kosugi, Kenzo, Oishi, Yumiko, Sato, Mizuto, Ueda, Ryo, Fujiwara, Hirokazu, Hikichi, Tetsuro, Noji, Shinobu, Oishi, Naoki, Ogawa, Kaoru, Kawakami, Yutaka, Ohira, Takayuki, Yoshida, Kazunari, Toda, Masahiro
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6917794/
https://ncbi.nlm.nih.gov/pubmed/31848332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-13640-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados